Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice
Lilit Grigoryan(Stanford University), Bali Pulendran(Stanford University), Robbert van der Most(GlaxoSmithKline (Belgium)), Elizabeth Kepl(University of Washington), Michael Murphy(University of Washington), Brooke Fiala(University of Washington), Neil P. King(University of Washington), Samuel Wrenn(University of Washington), Lauren Carter(University of Washington), Alexandra C. Walls(BioNTech (United States)), Rashmi Ravichandran(University of Washington), Mehul S. Suthar(Emory University), Deleah Pettie(University of Washington), Prabhu S. Arunachalam(Stanford University), Abigail Vanderheiden(Emory Healthcare), Audrey Lee(Pacific University Oregon), Natalie Brunette(University of Washington), Harry Kleanthous(Gates Foundation), Yupeng Feng(Stanford University), Katharine Floyd(Emory University), Benjamin Franco, David Novack(Dynavax Technologies (United States)), Claire Sydeman(University of Washington), Lilin Lai(Emory Healthcare), Robert L. Coffman(Cellular Research (United States)), David Veesler(Howard Hughes Medical Institute), Wei Luo(Jiangnan University), Jason S. McLellan(The University of Texas at Austin), Derek T. O’Hagan(GlaxoSmithKline (United States)), Marcos C. Miranda(University of Washington)
Cited by 55
Related Papers
Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein
|ACS Central Science|2020|1.1k
Systems biology of vaccination for seasonal influenza in humans
|Nature Immunology|2011|826
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
|bioRxiv (Cold Spring Harbor Laboratory)|2020|764